EP4051230A1 - Composition contenant des bactéries prébiotiques et des souches protectrices - Google Patents

Composition contenant des bactéries prébiotiques et des souches protectrices

Info

Publication number
EP4051230A1
EP4051230A1 EP20800592.6A EP20800592A EP4051230A1 EP 4051230 A1 EP4051230 A1 EP 4051230A1 EP 20800592 A EP20800592 A EP 20800592A EP 4051230 A1 EP4051230 A1 EP 4051230A1
Authority
EP
European Patent Office
Prior art keywords
cosmetic
composition according
strain
skin
protector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20800592.6A
Other languages
German (de)
English (en)
Inventor
Heike FÖLSTER
Stefan Gallinat
Daniel Richter
Petra SCHÖNDIENST
Svenja Lügger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of EP4051230A1 publication Critical patent/EP4051230A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • composition with probiotic bacteria and protector strains Composition with probiotic bacteria and protector strains
  • the present invention relates to a cosmetic or dermatological composition which comprises at least one probiotically active bacterial strain which has a positive effect on skin health when it settles on the skin, a protector strain of the genus Lacto bacillus and at least one cosmetic adjuvant.
  • the invention also relates to a method for the cosmetic or dermatological treatment of the skin, in which the composition of the present invention is applied to the skin.
  • the invention also relates to a method for producing the cosmetic or dermatological composition of the present invention.
  • US 2018/0104283 A1 describes a method in which bacterial strains naturally occurring on the skin are supplied to the skin in order to displace potentially pathogenic microorganisms.
  • WO 2016/172196 A1 describes a method for treating acne in a patient, in which live C. acnes strains are settled on the patient's skin.
  • it has repeatedly proven difficult to establish a sufficient amount of the metabolically active bacterial strains on the skin Since the skin is densely populated by bacteria, bacteria that are applied to the skin must first establish themselves in the microbiome, which is difficult due to the limited nutrients and the complex interactions within the various bacteria in the microbiome.
  • compositions and methods with which probiotic bacterial strains which have a positive effect on skin health can be settled in sufficient quantities on the skin and integrated into the microbiome.
  • a cosmetic composition which comprises or consists of at least the following components: a) at least one probiotically active bacterial strain which has a positive effect on the health of the skin when it settles on the skin; b) at least one protector strain of the genus Lactobacillus, which promotes the settlement of the probiotic bacterial strain; and c) at least one cosmetic auxiliary.
  • Lactobacillus strains protect the probiotic bacterial strains from being displaced by the existing microorganisms on the skin after they have been applied to the skin. For this reason, the Lactobacillus strains are referred to herein as "protector strains".
  • the composition according to the invention comprises, as the first component, a probiotically active bacterial strain which, when it settles on the skin, affects the skin health positively influenced.
  • probiotically effective means that the bacterial strain in question imparts health-promoting effects when administered to humans in sufficient quantities.
  • the term is used in connection with those bacterial strains that settle on the skin after administration to the skin, ie multiply through cell division, and have a positive effect on skin health through their presence in the skin flora.
  • bacteria of the genus Staphylococcus and Cutibacterium are particularly suitable as probiotically effective bacterial strains. These genera are those that are regularly represented in normal human skin flora.
  • the at least one probiotically effective bacterial strain belongs to a species which is selected from the group consisting of Staphylococcus epidermidis, Staphylococcus hominis and Cutibacterium acnes.
  • Staphylococcus epidermidis and Staphylococcus hominis are coagulase-negative, facultatively pathogenic, gram-positive bacteria that inhabit human skin and mucous membranes.
  • the at least one S. epidermidis strain and / or the at least one S. hominis strain is not an antimicrobial strain.
  • S. epidermidis strains and S. hominis strains are known which have developed resistance to conventional antibiotics such as penicillin and therefore cannot be treated with appropriate preparations. It has been described in the literature that S. epidermidis strains and S. hominis strains are actively involved in the control of the growth of pathogenic agents such as S. aureus strains in the natural skin flora. For this reason, the establishment of non-pathogenic S. epidermidis strains leads to an improvement in skin health.
  • the species C. acnes describes gram-positive, anaerobic, rod-shaped bacteria, which until 2016 were taxonomically only grouped together as Propionibacterium acnes.
  • the species includes pathogenic and non-pathogenic representatives. According to current knowledge, pathogenic representatives of this species, C. acnes, contribute significantly to the development of acne in humans, while non-pathogenic strains are important for maintaining a stable microbiome composition.
  • the species can be divided into three phylogenetically different types, which are referred to here as types I, II and III.
  • Type I bacteria are further subdivided into subtypes IA, IB and IC.
  • Subtype 1A is further divided into subgroups 1A1 and 1A2.
  • the composition according to the invention comprises at least one strain of the species C. acnes, this strain preferably belonging to (a) type I, subtype IA, subgroup IA2, (b) type I, subtype IB, or (c) type II heard.
  • the composition comprises one or more C. acnes strains of type I, subtype IA, subgroup IA2.
  • the composition comprises one or more C. acnes strains of type I, subtype IB.
  • the composition comprises one or more C. acnes strains of type II.
  • the composition according to the invention comprises in each case at least one strain of type I, subtype IA, subgroup IA2, at least one strain of type I, subtype IB, and at least one strain of type II. It is particularly preferred that the composition according to the invention comprises several strains of type I, subtype IA, subgroup IA2, in combination with several strains of type I, subtype IB, as well as several strains of type II.
  • composition of the present invention comprises a total amount of probiotic bacteria in the range of 10 4 -10 11 CFU / ml, and more preferably in the range of 10 7 -10 1 ° CFU / ml.
  • the composition according to the invention comprises, as a second component, at least one protector strain of the genus Lactobacillus, which promotes the settlement of the probiotically active bacterial strain.
  • Bacteria of the genus Lactobacillus are gram-positive, microaerophilic or anaerobic bacteria which taxonomically belong to the Lactobacillaceae family. These are gram-positive, usually rod-shaped bacteria that ferment sugar and carbohydrates into lactic acids. Bacteria of the genus Lactobacillus are particularly well known from the food industry, where they are often used as star cultures in the manufacture of dairy products. The genus includes various species that can be used without restriction within the scope of the present invention.
  • Suitable species which can serve as protector strains in the compositions of the present invention include Lactobacillus delbrueckii, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus delbrueckii subsp. delbrueckii, Lactobacillus delbrueckii subsp.
  • Lactis Lactobacillus acidophilus, Lactobacillus amylolyticus, Lactobacillus amylovorus, Lactobacillus aviaries, Lactobacillus bifermentans, Lactobacillus brevis, Lacto- bacillus casei, Lactobacillus coryniformis, Lactobacillus crispatus, Lactobacillus crustorum, Lactobacillus curvatus, Lactobacillus dextrinicus, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus hilgardii, Lactobacillus iners, Lactobacillus jensenii, Lactobacillus mali, Lactobacillus oryzae, Lactobacillus panis, Lactobacillus para- buchneri, Lactobacillus paracasei, Lactobacillus paralimentarius, Lactobacillus plantarum, Lactobacill
  • the composition of the present invention comprises two or more protector strains, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 Lactobacillus strains.
  • the at least one protector strain which is added to the composition according to the invention is a strain of the species Lactobacillus plantarum or Lactoba cillus rhamnosus.
  • the composition according to the invention comprises at least one strain of the species Lactobacillus plantarum and one strain of the species Lactobacillus rhamnosus.
  • the composition according to the invention comprises several strains of the species Lactobacillus plantarum and several strains of the species Lactobacillus rhamnosus.
  • the at least one protector strain produces an antibiotic substance.
  • the antibiotic substance can be a bacteriocin that is produced by the lactobacillus and secreted to the surrounding medi.
  • the protector strain preferably produces a bacteriocin which is selected from the group consisting of nisin, mersacidin, lactocin, acidocin B, and entereocin P.
  • the protector strain contained in the composition according to the invention produces 2 or more of the called bacteriocins.
  • the type and amount of the protector strain (s) are selected so that the at least one probiotically effective bacterial strain settles which is at least 2 times higher than the corresponding settlement of the bacterial strain in the absence of the protector trunk. It is even more preferred that the colonization of the at least one probiotically active bacterial strain is at least 5 times, at least 10 times, at least 20 times, at least 30 times, at least 40 times, at least 50 times, at least 75 times , at least 100 times, at least 500 times or is at least 1000 times higher than the corresponding colonization of the bacterial strain in the absence of the protector strain.
  • the effect of the protector strains can be measured in simple assays in which the composition of the present invention, which comprises at least one probiotically effective bacterial strain, at least one Lactobacillus strain, and at least one cosmetic adjuvant, is compared with a negative control.
  • the composition of the present invention comprises a total amount of bacteria of the genus Lactobacillus in the range of 10 4 -10 9 CFU / ml, and more preferably in the range of 10 6 -10 8 CFU / ml.
  • the protector strains can be contained in the composition in far smaller amounts compared to the probiotic strains. Since the protector strains only have to provide the probiotic strains with a growth advantage in the early phase of colonization of the skin, their permanent settlement is not necessary. Accordingly, the protector strains can be applied to the skin in significantly lower inoculation densities.
  • the at least one protector strain in the skin flora of the subject to whom the composition is administered. This means that the at least one protector strain does not reproduce or only insufficiently reproduces on the skin of the subject. It is preferred that after 24 hours, preferably after 48 hours and more preferably after 72 hours, the at least one protector strain can no longer be detected on the skin of the subject, or only in a small amount.
  • the composition according to the invention also comprises at least one cosmetic auxiliary.
  • This cosmetic auxiliary can be substances that are regularly used as auxiliary in cosmetic or dermatological products. These substances include antioxidants, solubilizers, vitamins, dyes, carriers, fillers, emulsifiers, humectants and the like.
  • the cosmetic auxiliary is glycerol, panthenol, ubiquinone Q10 or hyaluronic acid. Since the composition according to the invention is formulated for use on the skin, it will have a pH value which is in the neutral to slightly acidic range. Thus it is preferred that the composition have a pH of 4-8, and preferably 5-7.
  • composition according to the invention is preferably an emulsion.
  • This can be in the form of an oil-in-water emulsion or a water-in-oil emulsion.
  • the water content in the composition is less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, and particularly preferably less than 0.5% (weight / Weight).
  • the composition according to the invention is an anhydrous composition.
  • composition according to the invention is preferably in the form of a gel, a cream, an ointment or a lotion.
  • composition according to the invention preferably does not comprise any silicone oil, mineral oil or polyethylene glycol.
  • Cosmetic and dermatological compositions usually contain one or more preservatives.
  • lactic acid as a preservative. Since bacteria of the Lactobacillus genus convert sugar and carbohydrates to lactic acid, they are insensitive to lactic acid to a certain extent. Consequently, the addition of lactic acid does not lead to an inhibition of the metabolic activity of the at least one protector strain.
  • the composition of the invention comprises no further preservative besides lactic acid.
  • the present invention relates to a method for producing a cosmetic or dermatological composition as described above.
  • the method comprises steps in which a suspension or a lyophilizate of the respective bacterial strains is first produced. If it is a suspension, two separate suspensions can first be produced, which are then mixed with one another.
  • the first suspension contains the at least one probiotic strain of bacteria, and the second suspension contains the at least one Lactobacillus strain.
  • Both suspensions can be prepared by inoculating cell material in water or a suitable buffer. The two suspensions can then be mixed with one another and combined with the other constituents of the cosmetic or dermatological composition.
  • composition of the present invention is produced with lyophilisates of the bacterial strains
  • a lyophilisate can first be produced which comprises the at least one probiotic bacterial strain, and separately therefrom a second lyophilisate which comprises the at least one Lactobacillus strain.
  • the two lyophilizates can then either be mixed with one another and then brought into contact with the at least one cosmetic auxiliary substance, or mixed with the cosmetic auxiliary substance separately from one another.
  • first suspensions of the bacterial strains are mixed with one another, which are then subjected to freeze-drying so that a lyophilisate is obtained which contains all the bacterial strains that are in the cosmetic or dermatological composition of the present invention should be introduced.
  • This lyophilizate which contains both the at least one probiotic bacterial strain and the at least one Lactoba cillus strain, is then mixed with the at least one cosmetic adjuvant, and preferably with several cosmetic adjuvants, in order to provide the composition according to the invention.
  • Suitable methods for freeze-drying or lyophilization are well known to the person skilled in the art. Freeze drying involves freezing a product, such as a bacterial suspension, under reduced pressure and adding heat so that the frozen water in the product can be removed by sublimation. Most products can be dried to 1-5% residual moisture.
  • commercially available devices can be used for freeze-drying, such as the Lyovac TM devices from GEA (Berlin, Germany), the Gamma 2-20 freeze dryer LCM-1 from Christ (Osterode am Harz, Germany) or the Christ Martin TM Alpha 1-2 freeze dryer from Fisher Scientific GmbH (Schire, Germany).
  • the invention relates to a method for the cosmetic or dermatological treatment of the skin, comprising steps in which the above-described cosmetic or dermatological composition of the present invention is applied to the skin of a subject, preferably a human.
  • the area of skin to which the invention composition is applied has been carefully cleaned beforehand.
  • cleaning can be done with a surfactant-containing cleaning agent.
  • Cleaning agents which comprise benzoyl peroxide are particularly suitable for this purpose, although other substances can also be used in this context.
  • the composition is an anhydrous composition.
  • the bacterial strains can be present in the form of a lyophilizate in an oil phase. Only after the composition has been applied to the skin does the lyophilizate come into contact with water, which leads to the activation of the growth and metabolic activity of the bacteria
  • the oil phase can comprise oils customary in the field of cosmetics, such as, for example, lecithins, olive oil, sunflower oil, jojoba oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil and castor oil.
  • oils customary in the field of cosmetics such as, for example, lecithins, olive oil, sunflower oil, jojoba oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil and castor oil.
  • the composition is an aqueous composition.
  • the composition contains at least one aqueous phase in which the bacterial strains can be activated under suitable conditions.
  • compositions of the present invention may be in the form of a cosmetic preparation which is used as a mask.
  • the mask composition of the present invention is preferably based on an anhydrous powder which comprises at least one alginate, at least one calcium salt and at least one oil.
  • the bacteria can be present as a lyophilizate in the oil phase, as described above.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Botany (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une composition cosmétique ou dermatologique contenant : au moins une souche de bactéries biologiquement actives qui a une influence positive sur la santé de la peau lors de la sédimentation sur la peau ; une souche protectrice du genre Lactobacillus ; et au moins un adjuvant cosmétique. L'invention concerne en outre un procédé de traitement cosmétique ou dermatologique de la peau, la composition selon l'invention étant appliquée sur la peau. L'invention concerne également un procédé de préparation de la composition cosmétique ou dermatologique selon l'invention.
EP20800592.6A 2019-10-28 2020-10-28 Composition contenant des bactéries prébiotiques et des souches protectrices Pending EP4051230A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102019007507.2A DE102019007507A1 (de) 2019-10-28 2019-10-28 Zusammensetzung mit probiotischen Bakterien und Protektor-Stämmen
PCT/EP2020/080216 WO2021083920A1 (fr) 2019-10-28 2020-10-28 Composition contenant des bactéries prébiotiques et des souches protectrices

Publications (1)

Publication Number Publication Date
EP4051230A1 true EP4051230A1 (fr) 2022-09-07

Family

ID=73043235

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20800592.6A Pending EP4051230A1 (fr) 2019-10-28 2020-10-28 Composition contenant des bactéries prébiotiques et des souches protectrices

Country Status (3)

Country Link
EP (1) EP4051230A1 (fr)
DE (1) DE102019007507A1 (fr)
WO (1) WO2021083920A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115404189B (zh) * 2022-11-01 2023-01-13 山东锦鲤生物工程有限公司 棒状乳杆菌及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019079618A2 (fr) * 2017-10-20 2019-04-25 Naked Biome, Inc. Formulations pour le traitement des affections cutanées

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201206599D0 (en) * 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
EP3285872A4 (fr) 2015-04-20 2019-02-20 S-Biomedic NV Méthodes et compositions permettant de modifier la composition du microbiome de la peau à l'aide de mélanges complexes de souches bactériennes
US20180289751A1 (en) * 2015-05-05 2018-10-11 The Regents Of The University Of California Antimicrobial therapy
US20180104283A1 (en) 2016-10-13 2018-04-19 Gregory Gary Caputy Cosmetic skin treatment method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019079618A2 (fr) * 2017-10-20 2019-04-25 Naked Biome, Inc. Formulations pour le traitement des affections cutanées

Also Published As

Publication number Publication date
WO2021083920A1 (fr) 2021-05-06
DE102019007507A1 (de) 2021-04-29

Similar Documents

Publication Publication Date Title
EP2705140B1 (fr) Nouvelles bactéries d'acide lactique et compositions les contenant
DE69230496T2 (de) Tampon oder monatsbinde mit milchsäurebakterien
CN114901246A (zh) 新的皮肤护理组合物
JP2023133467A (ja) プロバイオティクスに基づいた組成物及びその使用
KR102692232B1 (ko) 프로피오니박테리움 아크네스로 인한 감염, 특히 여드름을 치료하는데 사용하기 위한 유산균 조성물
DE69827684T2 (de) Neue Lactobazillus-Stämme zur Behandlung von Störungen des Gastrointestinaltraktes
CN114901245B (zh) 新的皮肤护理组合物
EP0357162B1 (fr) Procédé de modification du petit-lait
CN114901252A (zh) 新的皮肤护理组合物
CN114929193A (zh) 新的皮肤护理组合物
EP4051230A1 (fr) Composition contenant des bactéries prébiotiques et des souches protectrices
CN114938629A (zh) 新的皮肤护理组合物
EP1296692B1 (fr) Utilisation d'une preparation constituee de ou contenant un minimum de lactoserum dissimule
WO2021018816A1 (fr) Masque facial à base d'alginate
US10555979B2 (en) Use of Lactobacillus paracasei GMNL-653 for preparing for a composition for alleviating axillary osmidrosis
EP4051222A1 (fr) Composition contenant des bactéries prébiotiques et de la licochalcone a
CN114929196A (zh) 新的皮肤护理组合物
KR102031358B1 (ko) 소엽 추출물을 유효성분으로 포함하는 미생물 균총 개선용 조성물
KR102031351B1 (ko) 호로파 추출물을 유효성분으로 포함하는 미생물 균총 개선용 조성물
KR102031359B1 (ko) 영실 추출물을 유효성분으로 포함하는 미생물 균총 개선용 조성물
EP0344786B1 (fr) Agent pour combattre et inhiber les clostridia
KR102031354B1 (ko) 계지 추출물을 유효성분으로 포함하는 미생물 균총 개선용 조성물
KR102031361B1 (ko) 정력자 추출물을 유효성분으로 포함하는 미생물 균총 개선용 조성물
KR102001241B1 (ko) 의이인 추출물을 유효성분으로 포함하는 미생물 균총 개선용 조성물
KR102031360B1 (ko) 자화지정 추출물을 유효성분으로 포함하는 미생물 균총 개선용 조성물

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220530

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BEIERSDORF AG

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250813